## **OPTIMA HEALTH PLAN**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization may be delayed.</u>

Drug Requested: Sirturo® (bedaquiline)

DRU	UG INFORMATION: Authorization may be delayed if incomplete.										
Drug 1	Form/Strength:										
		Length of Therapy:									
Diagn	osis: ICD Code, if appli	ICD Code, if applicable:									
Quan 20 wee	ntity Limit: 68 tablets for the first 28 days of treatment and then 24 takes.	ablets p	er 28 d	ays for	: the	e next					
each	<b>NICAL CRITERIA:</b> Check below all that apply. All criteria must be line checked, all documentation, including lab results, diagnostics, and/or quest may be denied.										
	Member is $\geq 18$ years old <u>AND</u> enrolled in a DOT ( <b>Directly Observed</b> )	Therapy	y) Progi	ram							
	AND										
	Diagnosis of Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (Please send <u>Sputum culture</u> for mycobacterium. Cultures provide purg sensitivity testing, and genotyping for epidemiologic purposes.)		pecies i	identif	ïcat	ion,					
	OR										
	□ Charts/Labs <u>MUST</u> be provided to document an M. tuberculosis isolisoniazid, rifampin, and possibly additional agents	ate that	is resist	ant to	at le	east					
	AND										
	Does the patient have diagnosis of latent or extra-pulmonary tuberculosi (Not indicated for treatment of latent, extra-pulmonary or drug sense)		Yes  3)	OR		No					
	AND										
	Sirturo® to be used in combination with three other drugs?		Yes	OR		No					
	AND										

(Continued on next page)

	Please mark all drugs the r	nember is using in combi	inati	on with Sirturo <sup>®</sup> : <b>(at</b>	least 3 must be marked)				
	Antibiotic Drugs (check each that the member is using in combination with Sirturo <sup>™</sup> ; at least three (3) must be marked.)								
	□ Amikacin	□ Capreomycin		Clofazimine	□ Cycloserine				
	□ Dapsone	□ Ethambutol		Ethionamide	☐ Isoniazid				
	□ Kanamycin	□ Linezolid		Ofloxacin	□ Pyrazinamide				
	□ Rifampicin	☐ Terizidone		Streptomycin	☐ 4-Aminosalicylic acid				
**	Use of samples to initi	ate therapy does not i	mee	et step edit/ preau	cessity will be required. thorization criteria.** r submitted chart notes.				
Patient 1			-						
Member Optima #:				Date of Birth:					
	er Name:								
	lumber: R NPI #:								
	R NP1 #: ed by Pharmacy and Therapeutic D/UPDATED: 8/27/2017; 8/30/20	s Committee: 10/15/2015 18; (Reformatted) 4/1/2021; 6/14.	/2021	÷ 8/12/2022;					